SCHEMBL5403729

SCHEMBL5403729

COc1ccc(OC)c(CCN(CCC(=O)O)C(=O)c2ccccc2-c2ccccc2C(=O)NCc2ccccc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.52
TAS1R3 Q7RTX0 1/20 0.51
TAS1R1 Q7RTX1 1/20 0.51
HPGD P15428 3/20 0.47
TP53 P04637 2/20 0.47
GLA P06280 1/20 0.47
CAPN1 P07384 1/20 0.47
MAPK8 P45983 1/20 0.47
HTT P42858 2/20 0.46
ALDH1A1 P00352 2/20 0.45
GAA P10253 1/20 0.45
PKM P14618 1/20 0.45
MAPT P10636 2/20 0.45
PPARA Q07869 2/20 0.43
PPARG P37231 1/20 0.43
NPC1 O15118 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
KDM4E B2RXH2 2/20 0.43
TSHR P16473 1/20 0.42
USP2 O75604 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4925143 0.97 TAS1R3 (0.50) RAB9ATAS1R3TAS1R1HPGDTP53
SCHEMBL5393968 0.96 RAB9A (0.60) RAB9ATAS1R3TAS1R1HPGDTP53
SCHEMBL4931263 0.95 TAS1R3 (0.48) RAB9ATAS1R3TAS1R1HPGDTP53
SCHEMBL4929811 0.94 TAS1R3 (0.47) RAB9ATAS1R3TAS1R1HPGDTP53
SCHEMBL4930254 0.94 TAS1R3 (0.47) RAB9ATAS1R3TAS1R1HPGDCAPN1
SCHEMBL5392453 0.93 RAB9A (0.52) RAB9ATAS1R3TAS1R1HPGDTP53
SCHEMBL5399253 0.93 TAS1R3 (0.56) RAB9ATAS1R3TAS1R1HPGDTP53
SCHEMBL4934241 0.93 RAB9A (0.52) RAB9ATAS1R3TAS1R1HPGDCAPN1
SCHEMBL4931672 0.93 RAB9A (0.52) RAB9ATAS1R3TAS1R1HPGDTP53
SCHEMBL4925833 0.93 PPARA (0.47) RAB9ATAS1R3TAS1R1HPGDCAPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB RAB9A 3132/4885TAS1R3 4642/4885TAS1R1 4377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.